NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
ObjectiveA prior longitudinal study demonstrates that free-water diffusion magnetic resonance imaging (dMRI) tracks progression in the substantia nigra (Ofori et al., 2015b). Here, we test the acute effects of antiparkinsonian medication on this established imaging progression marker for the first time.MethodsFifteen PD patients underwent dMRI OFF and ON-medication one day apart. ON-medication, patients were tested approximately 45 min after their usual dose of antiparkinsonian medication. OFF-medication, patients were tested after not taking antiparkinsonian medication for > 12 h. OFF and ON-medication was counter-balanced across subjects. For dMRI, we computed free-water and free-water corrected fractional anisotropy (FAt) within the following regions: caudate, putamen, substantia nigra, and subthalamic nucleus.ResultsON-medication significantly reduced parkinsonian motor symptoms compared with OFF-medication (p t) were not different between the OFF and ON-medication conditions.ConclusionsAdministration of an acute does of anti-parkinsonian medication in PD does not affect free-water and FAt in key nigrostriatal structures. Free-water and FAt biomarkers reflect the chronic state of the nigrostriatal circuit, and therefore are potential viable biomarkers for disease-modifying therapeutic studies in PD.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.